相关实验视频

Updated: Sep 17, 2025

Chronic Salmonella Infection Induced Intestinal Fibrosis

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

炎症性肠道疾病中的药理基因生物标志物:叙述性综述

Jatniel E Servian¹, Brianna Brady¹, Pritam Biswas¹

¹Department of Basic Sciences, St. Matthews University School of Medicine, Grand Cayman, Cayman Islands.

The Yale journal of biology and medicine

|July 1, 2025

概括

表观遗传生物标志物显示出预测炎症性肠病 (IBD) 治疗反应的前景. 这种方法可以通过超越遗传因素来个性化治疗和改善患者的结果.

科学领域:

胃肠道学和免疫学
药物遗传学药物遗传学
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

炎症性肠病 (IBD),包括克罗恩病和性结肠炎,是一个日益严重的全球健康问题.
目前IBD的诊断和治疗策略面临挑战,原因是诊断延迟和患者对治疗的反应变化.
仅仅遗传因素并不能完全解释IBD的治疗变异性,这表明需要额外的预测标志物.

研究的目的:

审查新兴的药理表观遗传学领域,以开发IBD中的预测生物标志物.
探索表观遗传修饰 (DNA甲基化,基因组修饰,ncRNAs) 作为IBD治疗反应的预测标记物的潜力.
突出最近的研究表明表观遗传分析在预测IBD患者结果中的有用性.

主要方法:

与IBD相关的药理生遗传学研究的文献综述.
对表观遗传修饰作为潜在生物标志物的研究进行分析.
评估表明表观遗传分析对治疗反应的预测能力的研究.

主要成果:

表观遗传分析已经显示出预测IBD患者治疗反应的潜力.
表观遗传修饰是理解和预测IBD发展和治疗结果的有希望的途径.
目前的研究虽然处于早期阶段,但支持在IBD中使用表观遗传生物标志物.

结论:

表观遗传生物标志物有可能预测IBD的治疗反应,补充遗传信息.
为了提高预测模型,需要对多样化的药物表观遗传群体进行进一步的研究.
将表观遗传生物标志物纳入临床实践可以个性化IBD治疗并改善患者护理.

关键词:

生物标志物生物标志物克罗恩氏病是什么?基因甲基化 DNA 甲基化表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.基质子的修改基质子的修改炎症性肠疾病炎症性肠病这是一个微型RNA.药理生遗传学药理生遗传学系统生物学系统生物学治疗结果的治疗结果.治疗反应对治疗的反应.性结肠炎是一种

更多相关视频

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...